2025-08-11
Precision BioAnalytics is a new Swedish biotech company offering high-sensitivity molecular diagnostics for research, infectious disease, and ATMPs.
A new Swedish biotech company, Precision BioAnalytics, is developing more sensitive and reliable molecular diagnostics to support research, clinical diagnostics, and the development of advanced therapies such as cell and gene therapies.
Founded by Mikael Kubista—a chemist, entrepreneur, and one of the world’s most cited researchers in molecular diagnostics—the company is now based at GoCo Health Innovation City in Mölndal, an emerging hub for ATMP innovation.
🔗 Read the original article (in Swedish)
Precision BioAnalytics aims to improve diagnostics by increasing sensitivity and reliability. One key target is tuberculosis, a bacterial disease that still causes over a million deaths annually worldwide.
According to Kubista, more affordable yet highly sensitive molecular diagnostics could play a critical role in detecting such infections earlier—making them more treatable.
This technology also supports precision diagnostics in cancer treatment, enabling earlier detection of circulating tumor DNA and improved monitoring of therapeutic response.
Kubista has over 30 years of experience and holds more than 20 patents. He previously co-founded several life science companies, including:
MultiD Analyses, developer of GenEx software for PCR and sequencing data
Life Genomics, Scandinavia’s leading private NIPT laboratory
Simsen Diagnostics, focused on ultra-sensitive cancer monitoring
TATAA Biocenter, a qPCR and gene expression center of excellence
His work in the SPIDIA consortium also contributed to the standardization of molecular diagnostic methods in Europe, now codified in 23 international standards.
Although his previous venture, TATAA Biocenter, was lost in a private equity deal, Kubista and his team have now returned with a renewed focus through Precision BioAnalytics.
The company collaborates closely with actors across the Swedish ATMP ecosystem, including:
Gothenburg University
Sahlgrenska University Hospital
Chalmers University of Technology
AstraZeneca
CCRM Nordic, a national infrastructure supporting cell line manufacturing for clinical trials
Together, these organisations aim to position Sweden—and particularly West Sweden—as a global leader in molecular diagnostics for advanced therapies.
Reliable molecular diagnostics are critical to the successful development and implementation of cell and gene therapies. With expertise rooted in both academic research and commercial innovation, Precision BioAnalytics is well-positioned to contribute to the growing demand for high-quality, standardised diagnostics across the life science sector.
The company’s location within GoCo Health Innovation City places it at the heart of one of Sweden’s most dynamic ATMP environments—where collaboration continues to drive innovation forward.